Magazine Article | May 2, 2022

A New Golden Age Of Psychedelic Therapy? Proceed With Caution

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

It was eye-opening for me, as I expect it will be for many readers of Life Science Leader, to learn that the Multidisciplinary Association for Psychedelic Studies (MAPS) aims to dose 1 million post-traumatic stress disorder (PTSD) patients with MDMA by 2031. MDMA, which MAPS founder and executive director Rick Doblin has called the “gentlest” of the psychedelic compounds currently being investigated for therapeutic use, is expected to receive the FDA’s blessing during the first half of 2024, if not sooner.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader